Portal de Periódicos da CAPES

Conclusions

1990; Wiley; Volume: 66; Issue: S5 Linguagem: Inglês

10.1002/cncr.1990.66.s5.1086

1097-0142

Louis Denis, Curtis Mettlin,

Bladder and Urothelial Cancer Treatments

CancerVolume 66, Issue S5 p. 1086-1089 ArticleFree Access Conclusions Louis Denis MD, FACS, Louis Denis MD, FACS EORTC, Antwerp, Belgium, and Cancer Control & Epidemiology, Roswell Park Memorial Institute, Buffalo, New York Search for more papers by this authorCurtis Mettlin PhD, Curtis Mettlin PhD EORTC, Antwerp, Belgium, and Cancer Control & Epidemiology, Roswell Park Memorial Institute, Buffalo, New York Search for more papers by this author Louis Denis MD, FACS, Louis Denis MD, FACS EORTC, Antwerp, Belgium, and Cancer Control & Epidemiology, Roswell Park Memorial Institute, Buffalo, New York Search for more papers by this authorCurtis Mettlin PhD, Curtis Mettlin PhD EORTC, Antwerp, Belgium, and Cancer Control & Epidemiology, Roswell Park Memorial Institute, Buffalo, New York Search for more papers by this author First published: September 1990 https://doi.org/10.1002/cncr.1990.66.s5.1086Citations: 13 Address for reprints: Louis Denis, MD, Department of Urology, AZ Middelheim, Lindendreef 1, Antwerp 2020, Belgium. Presented at the American Cancer Society Workshop on Combined Castration and Androgen Blockade Therapy in Prostate Cancer, Atlanta, Georgia, September 18–20, 1989. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419– 424. 1Beland G, Elhilali M, Fradet Y et al. Combination of castration and nilutamide (Anandron) versus castration alone for metastatic cancer of the prostate: A double-blind, randomized trial. J Urol in press. 1Keuppens F, Denis L, Smith P et al. Zoladex and flutamide versus bilateral orchiectomy: A randomized phase III EORTC 30853 study. Cancer 1990; 66(Suppl): 1045– 1057. 1Iversen P, Suciu S, Sylvester R, Christensen I, Denis L. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies: EORTC 30853 and DAPROCA 86. Cancer 1990; 66(Suppl): 1067– 1073. 1Suciu S, Sylvester R, Iversen P, Christensen I, Denis L. Comparability of EORTC and DAPROCA studies in advanced prostatic cancer. Cancer 1990; 66(Suppl): 1029– 1034. 1Dalesio O. Complete androgen blockade in prostate cancer: Organizing an overview. Cancer 1990; 66(Suppl): 1080– 1082. 1Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostatic cancer. In: VT DeVita, S Hellman, SA Rosenberg, eds. Important Advances in Oncology. Philadelphia: JB Lippincott, 1985; 193– 217. 1Labrie F, Bélanger A, Veilleux R et al. Rationale for a maximum androgen withdrawal in the therapy of prostatic cancer. In: BJA Furr, L Denis, eds. Clinical Oncology: International Practice and Research. Prostatic Cancer. London: Baillière Tindall, 1988; 597– 619. 1Schröder FH, Van Steenbrugge GJ. Rationale against total androgen withdrawal. In: BJA Furr, L Denis, eds. Clinical Oncology: International Practice and Research. Prostatic Cancer. London: Baillière Tindall, 1988; 621– 633. 1Bruchovsky N, Rennie PS, Goldenberg SL, Copping CML. Limitations of androgen withdrawal therapy of prostatic carcinoma: The next step? In: JP Karr, H Yamanaka (eds). Prostate Cancer: The Second Tokyo Symposium. New York, Elsevier, 1989; 1– 10. 1Poyet P, Labrie F. Comparision of the antiandrogenic/activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 1985; 42: 283– 288. 1El Etreby MF, Habenicht UF, Louton T, Nishino Y, Schroder FH. Effect of cyproterone acetate in comparison to flutamide and megestrol acetate in the ventral prostate, seminal vesicle and adrenal glands of adult male rats. Prostate 1987; 11: 361– 375. 1de Voogt HJ, Suciu S, Sylvester R et al. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from 2 European organization for research on treatment of cancer trials. J Urol 1989; 141: 883– 888. 1Simon R, Wittes RE. Methodologic guidelines for reports of clinical trials. Eur J Cancer Clin Oncol 1985; 21: 889– 891. 1Denis L, Mahler C. LHRH agonist combination treatment. In: M Motta, M Serio, eds. Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects. Amsterdam: Medicom, 1987; 85– 92. 1Dalesio O. Complete androgen blockade in prostate cancer: Organizing an overview. Cancer 1990; 66(Suppl): 1080– 1082. Citing Literature Volume66, IssueS5Supplement: American Cancer Society Workshop on Combined Castration and Androgen Blockade Therapy in Prostate CancerSeptember 1990Pages 1086-1089 ReferencesRelatedInformation